GCS
VKTX icon

Gordian Capital (Singapore)’s Viking Therapeutics VKTX Stock Holding History

Gordian Capital (Singapore)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50
Closed -$1.99K – 187
2024
Q4 		$1.99K Hold
50
– – ﹤0.01% 133
2024
Q3 		$3.17K Sell
50
-750
-94% -$44K ﹤0.01% 123
2024
Q2 		$42.4K Sell
800
-2,500
-76% -$164K 0.02% 102
2024
Q1 		$271K Buy
+3,300
New +$147K 0.2% 41

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Gordian Capital (Singapore)'s VKTX Position: Q1 2025 in Review

Gordian Capital (Singapore) sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 50 shares — an estimated $1.99K sold.

Gordian Capital (Singapore) first reported a position in VKTX in Q1 2024 and held it in 4 quarters. The position peaked at $271K in Q1 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Gordian Capital (Singapore) reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Gordian Capital (Singapore) sold 50 Viking Therapeutics shares in Q1 2025, an estimated $1.99K.
  • Gordian Capital (Singapore) first reported a position in Viking Therapeutics in Q1 2024 and held it in 4 quarters.
  • Gordian Capital (Singapore)'s Viking Therapeutics position peaked at $271K in Q1 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Gordian Capital (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.